Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) now offers income investors a dividend yield of 4.62%, a figure that towers over the broader market’s recent 1% average yield.

When share repurchases are factored in alongside dividends, the total shareholder yield climbs to approximately 5.5%, making NVO a compelling proposition for investors seeking meaningful returns.

The company’s shares currently trade at $39.06, within a 52-week range of $35.12 to $64.16, giving it a market capitalization of roughly $130 billion.

Unlike most American companies that distribute dividends quarterly, Novo Nordisk pays twice annually through an “annual” dividend and an “interim” payment, with combined distributions reaching $1.85 per share in 2026.

That figure represents extraordinary growth from the $0.62 per share paid in 2019 and more than double the $0.81 per share distributed in 2022, underscoring the company’s consistent commitment to rewarding shareholders.

A payout ratio of just 45% signals that the dividend is well-covered by earnings, leaving substantial headroom for further increases without straining the company’s finances.

On a valuation basis, NVO looks notably inexpensive, with a price-to-sales ratio of 3.5 sitting far below the stock’s five-year average of 8.1, while a forward price-to-earnings ratio of 12.3 sits close to its five-year average of 11.9.

Beyond income, the underlying business carries genuine growth potential, built on decades of leadership in diabetes care and an expanding footprint in the booming weight-loss drug market.

The company’s most strategically significant product in development is an oral GLP-1 drug, which eliminates the need for regular injections and is expected to launch across more than 20 markets in the near term.

Recent catalysts have also strengthened investor sentiment, including positive weight-loss clinical data and the approval of a hemophilia drug, while analysts have flagged that shares may be undervalued given a raised 2026 outlook.

The company is not without risks, having encountered some clinical trial setbacks and facing intensifying competition in the GLP-1 space, but its broader pipeline remains robust.

For investors balancing income needs with growth ambitions, Novo Nordisk presents a rare combination of an above-average yield, a disciplined payout structure, and a business operating at the center of one of healthcare’s fastest-growing therapeutic categories.